Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ifosfamide · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Ifosfamide | DRUG | - |
| Carboplatin | DRUG | - |
| Etoposide | DRUG | - |
| Rituximab | DRUG | - |
| 90Y Zevalin | DRUG | - |
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma * Persistent lymphoma after one or two previous chemotherapy regimens * Patients should not be considered candidates for high-dose chemotherapy *...
Ifosfamide is a small molecule being studied for the treatment of Non-Hodgkins Lymphoma. It is part of a combination regimen with carboplatin, etoposide, and rituxan, followed by zevalin, for patients with relapsed or refractory intermediate grade B-cell lymphoma.
Ifosfamide is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB.
Ifosfamide is in Phase 2 clinical development for Non-Hodgkins Lymphoma. It is an investigational drug and has not been approved by the FDA for this indication.
Ifosfamide has one completed Phase 2 clinical trial, identified as NCT00193505. The trial studied ifosfamide in combination with carboplatin, etoposide, and rituxan, followed by zevalin, in 40 patients with relapsed or refractory intermediate grade B-cell lymphoma in the United States.
Ifosfamide is a small molecule chemotherapeutic agent. It is an alkylating agent that works by cross-linking DNA, which inhibits DNA synthesis and leads to cell death, particularly in rapidly dividing cancer cells.